Shots:

• The P-III HUYGENS study evaluates Repatha + optimized statin therapy vs optimized statin therapy alone in patients with ACS for 52wks.
• The study met its 1EPs i.e.- improvement in the features of plaque morphology by increasing the fibrous cap thickness (75% vs 39%) as measured by OCT. The therapy also improved all 2EPs includes a reduction in maximum lipid arc (-57.5° vs -31.4°) & LDL-C level from 140 to 28 mg/dL with no new safety risks were observed
• Repatha is a mAb inhibiting PCSK9 & is approved in 76 countries- including the US- Japan- China- and EU. Previously- the GLAGOV study showed that therapy reduced plaque burden by decreasing plaque atheroma volume in CAD patients

| Ref: PR Newswire | Image: PR Newswire